Expression of exogenous wt-p53 does not affect normal hematopoiesis: implications for bone marrow purging

Area of Science:

• Oncology
• Gene Therapy
• Hematology

Background:

• Gene therapy for cancer aims to introduce tumor-suppressing genes into cancer cells.
• A key challenge is selectively targeting tumor cells to spare healthy ones.
• Wild-type p53 (wt-p53) can induce tumor suppression, but its effect on normal cells is crucial for therapeutic application.

Purpose of the Study:

• To evaluate the safety and efficacy of transducing wild-type p53 (wt-p53) into normal hematopoietic stem cells.
• To determine if wt-p53 gene transfer into normal bone marrow cells is detrimental.
• To explore the potential for wt-p53 gene therapy in leukemia treatment without specific tumor cell targeting.

Main Methods:

• Primary murine bone marrow (BM) cells were infected with two different wt-p53-recombinant retroviruses.
• In vitro assays assessed colony formation, morphology, and differentiation of transduced normal BM cells.
• The effect of the same viruses on v-src-transformed 32D cells was evaluated to confirm tumor suppression.

Main Results:

• Transduction of wt-p53 into normal murine BM cells did not impact in vitro colony formation, morphology, or differentiation.
• Exogenous wt-p53 expression in normal hematopoietic cells showed no adverse effects.
• The wt-p53-expressing retroviruses effectively suppressed the tumor phenotype in v-src-transformed 32D cells.

Conclusions:

• Wild-type p53 gene transfer is well-tolerated by normal hematopoietic cells.
• This suggests a potential strategy for leukemia gene therapy where wt-p53 can be delivered broadly to bone marrow cells.
• The approach may circumvent the need for highly specific tumor cell targeting in p53-based gene therapies for leukemia.